Evidence Hub

Editorial: proton pump inhibition – microbial complications beyond dysbiosis

J. Hov

Alimentary Pharmacology and Therapeutics, 2019

Abstract

© 2019 John Wiley & Sons Ltd 6. Yu K‐S, Bae K‐S, Shon J‐H, et al. Pharmacokinetic and pharmaco‐ dynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol. 2004;44:73‐82. 7. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of re‐ peated doses of TAK‐438 (vonoprazan), a novel potassium‐compet‐ itive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636‐648. 8. Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potas‐ sium‐competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50:751‐759. 9. Sunwoo J, Oh J, Moon SJ, et al. Safety, tolerability, pharmaco‐ dynamics and pharmacokinetics of DWP14012, a novel potas‐ sium‐competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018;48:206‐218. 10. Graham DY, Dore MP. Update on the use of vonoprazan: a compet‐ itive acid blocker. Gastroenterology. 2018;154:462‐466.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free